Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. Methods: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. Results: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. Conclusion: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.
PURPOSE: Speaker roles at major international oncology meetings mark academic visibility and leadership, yet representation of Latin America and Caribbean (LAC)–affiliated investigators remains poorly characterized. We evaluated LAC-affiliated faculty appearances at the ASCO Genitourinary Cancers Symposium (ASCO GU) from 2021 to 2025. METHODS: We systematically reviewed ASCO GU programs (2021-2025). Eligible sessions included General Session, Oral Abstract Session, and Rapid Oral Abstract Session. Affiliation was determined by institutional listing. We recorded total faculty appearances and stratified faculty appearances into invited educational, abstract-linked, and leadership roles. We additionally examined discussant and moderator appearances separately and identified the assigned speaker for each Oral or Rapid Oral presentation with at least one LAC-affiliated author. RESULTS: Among 84 eligible sessions comprising 540 faculty speakers, only six LAC-affiliated faculty appearances were identified, representing only 1% of the total faculty. No LAC-affiliated faculty appeared in 2021 or 2022, with minimal representation in subsequent years (2023: n = 1; 2024: n = 2; 2025: n = 3). By contrast, LAC-affiliated investigators were identified in 53 appearances as authors or coauthors in Oral or Rapid Oral sessions, predominantly affiliated with institutions in Brazil, Argentina, Chile, Mexico, and Colombia. Three of six LAC-affiliated faculty were linked to specific clinical trial presentations rather than independent educational lectures. CONCLUSION: LAC-affiliated investigators remain markedly under-represented among ASCO GU faculty despite robust scientific contributions, highlighting potential structural inequities and the need for deliberate initiatives to support equitable participation in international scientific discourse.